Trials / Recruiting
RecruitingNCT07172646
A Study of SRSD216 in Patients With Elevated Lipoprotein (a)
A Phase I/II, Randomized, Double Blind, Placebo Controlled, Dose-Escalation and -Expansion Study to Evaluate the Safety, Tolerability, PK, and PD of Subcutaneously Administered SRSD216 in Patients With Elevated Lipoprotein(a)
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 84 (estimated)
- Sponsor
- Sirius Therapeutics Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
This is a two-part study, intended to investigate the safety, tolerability, characteristics of PK and PD of single SC dose of SRSD216 and to identify a dose range for further studies in subjects with elevated Lp(a) level with or without ASCVD history.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SRSD216 injection | Administered SC. |
| DRUG | Placebo | Administered SC. |
Timeline
- Start date
- 2025-04-07
- Primary completion
- 2026-05-01
- Completion
- 2027-04-01
- First posted
- 2025-09-15
- Last updated
- 2026-01-06
Locations
1 site across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07172646. Inclusion in this directory is not an endorsement.